人重组骨形态蛋白-2在脊柱融合中并发症的研究  

Research progress of recombinant human bone morphogenetic protein-2 in complications of spinal fusion

作　　者：李奭慧 李忠海[2] Li Shihui;Li Zhonghai(Dalian Medical University,First Clinical College,Dalian Liaoning,116600,China;Department of Orthopedics,First Affiliated Hospital of Dalian Medical University,Key Laboratory of Molecular Mechanism for Repair and Remodeling of Orthopedic Diseases,Dalian Liaoning,116600,China)

机构地区：[1]大连医科大学第一临床学院,辽宁大连116600 [2]大连医科大学附属第一医院骨科辽宁省骨相关疾病修复重塑分子机制重点实验室,辽宁大连116600

出　　处：《生物骨科材料与临床研究》2020年第3期55-58,共4页Orthopaedic Biomechanics Materials and Clinical Study

基　　金：辽宁省自然科学基金指导计划(20170540294);辽宁省高等学校基本科研项目(LQ2017022);辽宁省“兴辽英才计划”(XLYC1807131)。

摘　　要：自体骨移植物具有天然的骨诱导和骨传导特性,是骨移植材料中的金标准,但其存在局限性。目前重组人骨形态发生蛋白-2(rhBMP-2)被广泛应用于临床中以提高脊柱融合率。但其应用范围远超美国食品药品监督管理局(FDA)标准,同时也出现了很多并发症。因此研制出新型骨修复材料成为了目前亟待解决的问题。Autogenous bone graft has natural bone induction and conduction properties and is still the gold standard of bone graft materials.However,it has limitations.It is an urgent problem to develop new bone repair materials.rhBMP-2 has been widely used in clinical practice to improve the success rate of spinal fusion.But at present,the application scope of rhBMP-2 is far beyond the standard of the food and drug administration(FDA),and there are also many complications.

关 键 词：重组人骨形态发生蛋白-2 脊柱融合 并发症 

分 类 号：R318[医药卫生—生物医学工程]